Capricor Therapeutics

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Capricor Therapeutics reports strong Q4 performance and advances DMD therapy

Capricor Therapeutics showcased strong financial performance, progress in DMD therapy, and strategic partnerships with Nippon Shinyaku and NS Pharma.
The company faces challenges in FDA interactions, share sales, and potential acquisition decisions, but opportunities lie in market expansion and community engagement.
Overall, Capricor's confidence in its therapies and partnerships positions it well for future growth and impact in the Duchenne Muscular Dystrophy space.
The call concluded with gratitude towards participants, supporters, and the Capricor team, highlighting a positive outlook for the company's future endeavors.

Capricor Therapeutics advances DMD programs and secures Japan distribution

Capricor Therapeutics made significant progress in Q1 2023 with advancements in DMD programs, manufacturing, and clinical trials.
While facing financial losses, the company's strategic strengths include FDA discussions, partnerships, and international expansion.
Challenges in financial stability and operational efficiency need to be addressed, but opportunities in funding, market expansion, and innovation are promising.

Capricor Therapeutics reports Q2 progress with positive clinical outcomes

Capricor Therapeutics showcased solid financial performance amid ongoing R&D investments, with a focus on advancing innovative therapies for Duchenne muscular dystrophy.
The company's strengths lie in positive clinical trial outcomes, regulatory support, and strategic board additions, positioning Capricor for future growth and success.
Challenges include financial sustainability, trial coordination, and manufacturing scalability, which require careful management to navigate effectively.
Opportunities in new indications, partnerships, upcoming milestones, and technology advancement offer avenues for expansion, value creation, and competitive differentiation.

Capricor Therapeutics achieves enrollment goal, eyes FDA approval acceleration

Capricor Therapeutics is making significant strides in its clinical trials and manufacturing capabilities, supported by a strong financial position. While challenges exist in managing expenses and navigating regulatory processes, the company is well-positioned to capitalize on growth opportunities in the biopharmaceutical sector.

Capricor Therapeutics reports positive trial results and strategic partnerships for growth

Capricor Therapeutics' Q4 2023 performance reflects a strong financial position but with a net loss, driven by positive trial results for CAP-1002 in DMD.
The company's strengths include successful trial outcomes, strategic partnerships, and advancements in exosome technology development.
Challenges include operational losses, regulatory hurdles, and market competition, while opportunities exist in partnerships, FDA interactions, and technology development.
Overall, Capricor Therapeutics is poised for growth with a focus on commercialization, regulatory progress, and expanding therapeutic applications.

Capricor Therapeutics excels in Q1 2024, poised for market expansion

Capricor Therapeutics shows strong financial performance and progress in DMD trial, positioning CAP-1002 favorably in the market.
Strategic focus on regulatory alignment, commercial readiness, and potential expansions highlight growth opportunities.
Challenges in regulatory compliance, operational execution, and market competition require proactive management strategies.
Overall, Capricor's advancements in therapy development and market positioning indicate a promising outlook for future growth.

Capricor Therapeutics reports Q3 progress, eyes market expansion opportunities

Capricor Therapeutics demonstrated financial resilience with steady revenue growth and a strong cash position, despite a net loss.
The company's focus on product development, market expansion, and strategic collaborations underscores a commitment to innovation and growth.
While facing challenges in managing expenses and navigating regulatory complexities, Capricor is well-positioned to capitalize on opportunities in new therapeutic areas and market access.
Overall, Capricor's progress on deramiocel, manufacturing scale-up, and future development plans signal a promising trajectory for sustained growth and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS-

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, HOPE-2 Final Data Submitted for Publication-

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Company's ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference.

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

-Capricor's Findings Support Expansion Across Multiple Therapeutic Targets-

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Capricor Therapeutics, Inc.'s (CAPR) CEO Linda Marbán on Q1 2021 Results - Earnings Call Transcript

---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy-

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET

Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13

Capricor Therapeutics (NASDAQ: CAPR) has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of the Company's exosome technology portfolio. Under the terms of the agreement, Capricor has exclusive rights to develop, manufacture, and commercialize, with the right to sublicense, IP related to exosome technology for applications across both vaccine and therapeutic areas.

Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact

The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) went from a previous close of $3.95 to over $4.20 pre-market. This is why it happened.

CAPR Stock: From $3.95 To Over $4.20 Pre-Market Explanation

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call Transcript

Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes-

Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles-

Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and impacts approximately six per 100,000 individuals in North America and Europe. Current treatments are inadequate because they only address a small segment of the Duchenne muscular dystrophy population, leaving a huge unmet need.

Capricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In Play

-Technology Licensed from Johns Hopkins University-

Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19

Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients

Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19

Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript

Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -Development of Safe, Non-toxic Exosome Formulation Capable of Delivering Functional mRNA in vitro and in vivo- - Platform Expansion Underway Using Engineered Exosomes -

Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins

News for Capricor Therapeutics Stock (CAPR)